Neurogene to Participate in Upcoming Conferences
Neurogene Inc. (NGNE)
Company Research
Source: Business Wire
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:Goldman Sachs 45th Annual Global Healthcare ConferenceFormat: Management will present a corporate overview and participate in investor meetingsDate: Wednesday, June 12 at 1:20 p.m. ET2024 IRSF (International Rett Syndrome Foundation) Rett Syndrome Scientific MeetingFormat: Management and Bernhard Suter, M.D., Medical Director of the Blue Bird Circle Rett Center at Texas Children’s Hospital, Associate Professor of Pediatrics and Neurology at Baylor College of Medicine, and principal investigator in the Phase 1/2 NGN-401 gene therapy trial for Rett syndrome, will present interim safety data from the NGN-401 trialDate: Tuesday, June 18 at 5:15 p.m. MT (poster presentation), and Wednesday, June 19 at 11:30
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Inc. (NASDAQ: NGNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.MarketBeat
- Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation [Yahoo! Finance]Yahoo! Finance
- Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome [Yahoo! Finance]Yahoo! Finance
- Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett SyndromeBusiness Wire
- Neurogene Inc. (NASDAQ: NGNE) was upgraded by analysts at Baird R W to a "strong-buy" rating.MarketBeat
NGNE
Earnings
- 5/10/24 - Beat
NGNE
Sec Filings
- 6/21/24 - Form 8-K
- 6/18/24 - Form 8-K
- 6/17/24 - Form 4
- NGNE's page on the SEC website